Elevated concentrations of interleukin-6 have been demonstrated to be an important key
factor in COVID-19 host immune impairment. It represents an important prognostic factor of …

Tocilizumab is an IL‐6 receptor antagonist with the ability to suppress the cytokine storm in
critically ill patients infected with severe acute respiratory syndrome‐coronavirus 2 (SARS …

Background COVID-19 is an ongoing threat to society. Patients who develop the most
severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has …

Objective: To evaluate the use of tocilizumab in a community hospital setting for critically ill
patients with severe COVID-19. Design: A retrospective case series Setting: Five community …

Background Due to the lack of proven therapies, we evaluated the effects of early
administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab …

Background Current evidence suggests an important role of the interleukin‐6 (IL‐6) pathway
in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐related cytokine …

Background The treatment of severe cases of COVID‐19 disease remains a dilemma so far,
because there is no approved therapy for it. This study aimed to estimate the therapeutic …

The severe acute respiratory syndrome coronavirus‑2 (SARS‑CoV‑2) pandemic is a
significant global issue that has major implications for the healthcare system. The mortality …

Objective The aim of this retrospective observational study is to analyse clinical, serological
and radiological predictors of outcome in patients with COVID-19 pneumonia treated with …